Rodabe N. Amaria

The University of Texas MD Anderson Cancer Center

MedicineBiochemistry, Genetics and Molecular BiologyImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 27 papers. Top paper: “Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results”.

Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results

Nature Medicine(2023)10.1038/s41591-022-02170-x

N/A

1.9DataRank · unranked

83 citations

Sherise D. Ferguson, Roland L. Bassett, Alexandra P. Foster, Ida John, Tarin Hennegan +32 more

Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS -mutant Melanoma

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-3872

N/A

1.6DataRank · unranked

44 citations

Lisa Zimmer, Kevin B. Kim, Jeffrey A. Sosman, Paolo A. Ascierto, Michael A. Postow +10 more

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

Science(2018)10.1126/science.aan4236

N/A

1.3DataRank · unranked

4585 citations

C. N. Spencer, Luigi Nezi, Alexandre Reuben, Miles C. Andrews, Tatiana V. Karpinets +89 more

Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-006822

N/A

1.3DataRank · unranked

52 citations

Anne Knisely, David Vining, Scott Kopetz, Michael J. Overman, Milind Javle +16 more

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade

Cancer Discovery(2016)10.1158/2159-8290.cd-15-1545

N/A

1.0DataRank · unranked

1012 citations

Whijae Roh, Alexandre Reuben, Zachary A. Cooper, Christine N. Spencer, Peter A. Prieto +39 more

Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade

Nature Medicine(2021)10.1038/s41591-021-01406-6

N/A

0.910DataRank · unranked

429 citations

Connie P. M. Duong, Vancheswaran Gopalakrishnan, Valerio Iebba, W. S. Chen, Lisa Derosa +66 more

Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti‐CTLA4 and anti‐PD1 combination immunotherapy: Incidence, management, and clinical benefit

Cancer(2021)10.1002/cncr.34004

N/A

0.890DataRank · unranked

21 citations

Sahira Farooq, Macartney Welborn, Rodabe N. Amaria, Susan Y. Chon, Adi Diab +13 more

Neoadjuvant relatlimab and nivolumab in resectable melanoma

Nature(2022)10.1038/s41586-022-05368-8

N/A

0.874DataRank · unranked

339 citations

Michael A. Postow, Elizabeth M. Burton, Michael T. Tetzlaff, Merrick I. Ross, Carlos A. Torres‐Cabala +35 more

Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

Nature(2022)10.1038/s41586-022-04833-8

N/A

0.731DataRank · unranked

130 citations

Michael G. White, Miles C. Andrews, Manoj Chelvanambi, Russell G. Witt, Joseph R. Daniele +60 more

Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002449

N/A

0.574DataRank · unranked

45 citations

Rodabe N. Amaria, Amer Najjar, Laszlo Radvanyi, Cara Haymaker, Marie-Andrée Forget +18 more

Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma

Annals of Oncology(2020)10.1016/j.annonc.2020.07.016

N/A

0.538DataRank · unranked

35 citations

Chandra Mani Adhikari, Serigne Lo, Robert V. Rawson, Rodabe N. Amaria, Alexander M. Menzies +16 more

Neoadjuvant Immunotherapy for Locally Advanced Melanoma

Current Treatment Options in Oncology(2020)10.1007/s11864-020-0700-z

N/A

0.470DataRank · unranked

22 citations

Rodabe N. Amaria, Meredith S. Pelster

Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-1060

N/A

0.434DataRank · unranked

17 citations

Yuzhong Jeff Meng, Marie‐Andrée Forget, Tatiana V. Karpinets, Katarzyna Tomczak, Chip Stewart +22 more

Identification of MicroRNA–mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes

Cancers(2021)10.3390/cancers13215301

N/A

0.385DataRank · unranked

12 citations

Michael G. White, Russell G. Witt, Anik Banerjee, Michael A. Davies, Guangchun Han +18 more

Tumor infiltrating lymphocyte (TIL) harvest and ex vivo expansion from primary and metastatic (met) uveal melanoma (UM) tumors.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.9513

N/A

0.350DataRank · unranked

6 citations

Marie‐Andrée Forget, Firas Kreidieh, Meredith Pelster, Michael A. Davies, Rodabe N. Amaria +3 more

Neoadjuvant-adjuvant pembrolizumab in clinical stage IIB/C melanoma.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.9502

N/A

0.345DataRank · unranked

9 citations

Mohammad Saad Farooq, Phyllis A. Gimotty, Tara C. Mitchell, Ravi K. Amaravadi, Lynn M. Schuchter +11 more

Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi -NT in Patients with Advanced Solid Tumors

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-3952

N/A

0.330DataRank · unranked

8 citations

Filip Jankú, Siqing Fu, Ecaterina E. Dumbrava, David S. Hong, Daniel D. Karp +20 more

Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma

Nature(2023)10.1038/s41586-023-05892-1

N/A

0.165DataRank · unranked

2 citations

Michael A. Postow, Elizabeth M. Burton, Michael T. Tetzlaff, Merrick I. Ross, Carlos A. Torres‐Cabala +35 more

Metabolic plasticity of T-cell therapies: multi-omic profiling of interacting human tumor-infiltrating lymphocytes and autologous tumor adoptive cell therapy

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.09.28.509590

N/A

0.104DataRank · unranked

1 citations

Cara Haymaker, Jonathan L. Robinson, Michal Harel, Caitlin Creasy, Jay R T. Adolacion +12 more

Patients with advanced solid cancers treated with ERK inhibitors exhibit pseudo-progession in lymphatic nodes.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3138

N/A

0DataRank · unranked

0 citations

Daniel D. Karp, Abha Adat, Timothy A. Yap, Siqing Fu, Jordi Rodon Ahnert +12 more

Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity

Cancer Immunology Immunotherapy(2020)10.1007/s00262-020-02748-9

N/A

0DataRank · unranked

34 citations

Shruti Malu, Jodi A. McKenzie, Soraya Zorro Manrique, Elien M. Doorduijn, Rina M. Mbofung +24 more

Gynecologic tract melanoma in the contemporary therapeutic era: High rates of local and distant disease progression

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.09.026

N/A

0DataRank · unranked

13 citations

Morgan A. Farr, Priyadharsini Nagarajan, Joel Ho, Andrew J. Bishop, Anuja Jhingran +7 more

Immune-related adverse events and symptom burden in patients with melanoma receiving adjuvant immune checkpoint inhibitor.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps12147

N/A

0DataRank · unranked

0 citations

Teresa Kuś, Salah-Eddine Bentebibel, Jennifer L. McQuade, Isabella Claudia Glitza, Rodabe N. Amaria +11 more

Data from Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma

(2023)10.1158/1078-0432.c.6532311

N/A

0DataRank · unranked

0 citations

Lisa Zimmer, Kevin B. Kim, Jeffrey A. Sosman, Paolo A. Ascierto, Michael A. Postow +10 more

Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-008735

N/A

0DataRank · unranked

79 citations

Omid Hamid, Krishna V. Komanduri, Rodabe N. Amaria, Marcus O. Butler, John B.A.G. Haanen +6 more

Androgen receptor activity promotes resistance to BRAF-targeted melanoma therapy

Research Square(2020)10.21203/rs.3.rs-58480/v1

N/A

0DataRank · unranked

0 citations

Christopher P. Vellano, Michael White, Miles C. Andrews, Joseph R. Daniele, Mark Titus +41 more

Successful tumor-infiltrating lymphocyte (TIL) growth from uveal melanoma (UM) using a three-signal (3.0) method.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3027

N/A

0DataRank · unranked

0 citations

Marie‐Andrée Forget, Stephen K. Gruschkus, Cara Haymaker, Chantale Bernatchez, Patrick Hwu +4 more